Statins, Tregs and cancer

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 483-484

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^c  

^a Servizio Sanitario ^*  (United States)

^b Ospedale di San Vito al Tagliamento ^*  (Italy)

^c Ospedale di San Vito al Tagliamento   (Italy)

Author keywords

Cancer; Statins; Tregs

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; LETTER; LIVER CELL CARCINOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

AGE FACTORS; AGED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOCOMPROMISED HOST; LIVER NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 38049002409     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.09.028     Document Type: Letter

References (18)

1. Mausner-Fainberg K., Luboshits G., Mor A., et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4 + CD25+ T cells. Atherosclerosis (2007) 10.1016/j.atherosclerosis.2007.07.031
2. Mallat Z., Ait-Oufella H., and Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 16 (2005) 518-524
3. Yakirevich E., and Resnick M.B. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 25 (2007) 2506-2508
4. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 (2007) 1167-1174
5. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
6. Bates G.J., Fox S.B., Han C., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 (2006) 5373-5380
7. Kobayashi N., Nobuyoshi H., Yamagami W., et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13 (2007) 902-911
8. Carreras J., Lopez-Guillermo A., Fox B.C., et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108 (2006) 2957-2964
9. Alvaro T., Lejeune M., Salvado M.T., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytoxic and regulatory T cells. Clin Cancer Res 11 (2005) 1467-1473
10. Alawi A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 (2007) 409-418
11. Newman T.B., and Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA 275 (1996) 55-60
12. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
13. The PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
14. The LIPID Investigators. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 134 (2001) 931-940
15. The Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years or older with stable coronary heart disease. Ann Intern Med 147 (2007) 1-9
16. Hoffmann P., Roumeguere T., and van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355 (2006) 2705-2707
17. The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
18. O'keefe Jr. J.H., Cordain L., Harris W.H., Moe R.M., and Vogel R. Optimal low-density lipoprotein is 50-70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 43 (2004) 2142-2146